Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Eosinophil trafficking in asthma.

A J Wardlaw1

  • 1Division of Respiratory Medicine, Leicester-Warwick Medical School, Glenfield Hospital.

Clinical Medicine (London, England)
|July 12, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The role of oral methotrexate as a steroid sparing agent in refractory eosinophilic asthma.

Chronic respiratory disease·2017
Same author

Responsiveness to oral prednisolone in severe asthma is related to the degree of eosinophilic airway inflammation.

Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology·2017
Same author

Allergic Fungal Airway Disease.

Journal of investigational allergology & clinical immunology·2016
Same author

The relationship between biomarkers of fungal allergy and lung damage in asthma.

Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology·2016
Same author

Protein phosphatase 5 mediates corticosteroid insensitivity in airway smooth muscle in patients with severe asthma.

Allergy·2016
Same author

Farewell.

Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology·2015
Same journal

Resident doctor workforce wellbeing worldwide: lessons between the United Kingdom and Australia.

Clinical medicine (London, England)·2026
Same journal

Premature ventricular complexes.

Clinical medicine (London, England)·2026
Same journal

Heart failure with preserved ejection fraction (HFpEF): diagnosis and management for the general physician.

Clinical medicine (London, England)·2026
Same journal

Trends and Widening Inequities in Cardiovascular-Kidney-Metabolic Involvement in Cardiovascular Mortality: A National Spatiotemporal Analysis, 2014-2023.

Clinical medicine (London, England)·2026
Same journal

Educating current and future healthcare professionals on evidence-based sustainable medicine.

Clinical medicine (London, England)·2026
Same journal

UK Foundation Programme training needs a national minimum standard for advanced life support.

Clinical medicine (London, England)·2026
See all related articles

Asthma involves a significant increase in eosinophils due to multiple migration steps. Targeting key molecules like interleukin-5 (IL-5) and adhesion proteins can inhibit this eosinophil recruitment.

Area of Science:

  • Immunology
  • Respiratory Medicine
  • Cell Biology

Background:

  • Asthma is characterized by a substantial increase in eosinophils within the bronchial mucosa compared to neutrophils.
  • This eosinophilia results from sequential, multi-stage increases in eosinophil migration and survival.

Purpose of the Study:

  • To elucidate the specific cellular and molecular mechanisms driving eosinophil recruitment in asthma.
  • To identify potential therapeutic targets for inhibiting eosinophil migration in asthmatic airways.

Main Methods:

  • The study analyzes the cumulative effects of several biological processes influencing eosinophil migration.
  • Key molecular pathways and cellular interactions, including cytokine signaling and adhesion molecule involvement, are examined.

Related Experiment Videos

Main Results:

  • Eosinophil recruitment is mediated by allergen-specific T helper 2 lymphocytes producing interleukin-5 (IL-5), IL-4, and IL-13.
  • Specific stages include increased bone marrow production (IL-5), enhanced adhesion to endothelium (P-selectin/PSGL-1, VLA-4/VCAM-1), directed chemotaxis (CC chemokines), and prolonged survival (IL-5).
  • These processes collectively lead to a 50-fold increase in mucosal eosinophils.

Conclusions:

  • Inhibiting IL-5, IL-4, IL-13, VLA-4, PSGL-1, or CC chemokine receptor 3 offers potential therapeutic strategies.
  • Targeting these specific molecular pathways can significantly reduce eosinophil recruitment in asthma patients.